Paclitaxel ( DrugBank: Paclitaxel )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
| 85 | Idiopathic interstitial pneumonia | 8 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00055133 (ClinicalTrials.gov) | September 2002 | 19/2/2003 | A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis | A Phase 2 Open-Label Clinical Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Micellar Paclitaxel for Injection | Angiotech Pharmaceuticals | NULL | Completed | 21 Years | 70 Years | Both | 50 | Phase 2 | United States |
85. Idiopathic interstitial pneumonia
Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs071180049 | 23/05/2017 | 15/03/2019 | Japanese Intergroup Study of Nintedanib for NSCLC with IPF | A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis - J-SONIC | Advanced Non-small cell lung cancer with idiopathic pulmonary fibrosis | carboplatin + nab-paclitaxel carboplatin + nab-paclitaxel + nintedanib | Okamoto Isamu | Otsubo Kohei | Not Recruiting | >= 20age old | Not applicable | Both | 240 | Phase 3 | Japan |
| 2 | JPRN-UMIN000026799 | 2017/05/12 | 01/04/2017 | A randomized phse 3 study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis | A randomized phse 3 study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis - Japanese Intergroup Study of Nintedanib for NSCLC with IPF (J-SONIC) | Non-small-cell lung cancer with idiopathic pulmonary fibrosis | A: 4 cycles of Carboplatin (AUC 6, day 1) plus nab-Paclitaxel (100 mg/m2, day 1, 8, 15) repeated every 3 weeks B: 4 cycles of Carboplatin (AUC 6, day 1) plus nab-Paclitaxel (100 mg/m2, day 1, 8, 15) in combination with nintedanib (150 mg B.I.D, daily) repeated every 3 weeks followed by single-agent administration of nintedanib (150 mg B.I.D, daily) | Research Institute for Diseases of the Chest, Kyushu University | NULL | Complete: follow-up continuing | 20years-old | Not applicable | Male and Female | 240 | Phase 3 | Japan |
| 3 | JPRN-UMIN000021591 | 2016/04/04 | 01/04/2016 | The pilot study of Nintedanib and Carboplatin plus Paclitaxel for advanced non-small cell lung cancer with idiopathic interstitial pneumonia | The pilot study of Nintedanib and Carboplatin plus Paclitaxel for advanced non-small cell lung cancer with idiopathic interstitial pneumonia - The pilot study of Nintedanib and Carboplatin plus Paclitaxel for advanced non-small cell lung cancer with idiopathic interstitial pneumonia | Advanced non-small cell lung cancer with idiopathic interstitial pneumonia | carboplatin AUC6 D1 paclitaxel 200mg/m D1 tryweekly 4cycle nintedanib 150mg twice daily | Hirosaki University Graduate School of Medicine | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 30 | Not selected | Japan |
| 4 | JPRN-jRCTs051180149 | 24/01/2013 | 20/03/2019 | CBDCA plus PTX for NSCLC (squamous) with IP | Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia - IP001 | Squamous cell lung cancer Lung cancer | Carboplatin (AUC=5) given on day1 and paclitaxel (70mg/m2) given on days 1,8,15 every 4weeks until disease progression or unmanageable toxicity. | Katakami Nobuyuki | NULL | Complete | >= 20age old | Not applicable | Both | 40 | Phase 2 | Japan |
| 5 | JPRN-jRCTs061180046 | 17/01/2013 | 12/03/2019 | CBDCA, PTX and BV for NSCLC (non-sq) with IP | Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia - IP002 | Non-squamous, non-small cell lung cancer Lung cancer | Carboplatin (AUC=5) given on day1, paclitaxel (70mg/m2) given on days 1,8,15 and bevacizumab (15mg/m2) on day 1 every 4weeks until disease progression or unmanageable toxicity. | Katakami Nobuyuki | NULL | Complete | >= 20age old | Not applicable | Both | 35 | Phase 2 | Japan |
| 6 | JPRN-UMIN000018322 | 2012/12/01 | 15/07/2015 | Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia | advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia | carboplatin AUC = 5, day1 paclitaxel 70mg/m2, day1 ,8 ,15 bevacizumab 15mg/kg, day1 every 4 weeks, 4-6 cycle | IP lung cancer study group | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 35 | Phase 2 | Japan | |
| 7 | JPRN-UMIN000018248 | 2012/12/01 | 09/07/2015 | Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia | advanced squamous cell lung cancer with idiopathic interstitial pneumonia | Carboplatin AUC = 5 , day1 Paclitaxel 70mg/m2, day1,8,15 4-6 cycle | IP lung cancer study group | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 40 | Phase 2 | Japan | |
| 8 | JPRN-UMIN000015929 | 2007/05/10 | 12/12/2014 | Prospective observational study of Idiopathic pulmonary fibrosis with Non-small-cell lung cancer(LOGIK0603) | Idiopathic pulmonary fibrosis | Carboplatin/paclitaxel combination therapy (dosage and administration) Paclitaxel (PAC):175-200mg/m2 at day1 and carboplatin (CBDCA): AUC 5-6min.mg/mL at day1 are administered and repeated every 21 days as 1 course and the treatment is aimed for more than 3 courses. *The study is discontinued at that point if it becomes PD. | Lung Oncology Group in Kyushu, Japan (LOGIK) | NULL | Complete: follow-up complete | 20years-old | 75years-old | Male and Female | 60 | Not selected | Japan |